Javascript is not activated in your browser. This website needs javascript activated to work properly.
You are here

Preclinical evaluation of (111)In-DTPA-INCA-X anti-Ku70/Ku80 monoclonal antibody in prostate cancer.

  • Susan Evans Axelsson
  • Oskar Vilhelmsson Timmermand
  • Charlotte Welinder
  • Carl Ak Borrebaeck
  • Sven-Erik Strand
  • Thuy Tran
  • Bo Jansson
  • Anders Bjartell
Publishing year: 2014
Language: English
Pages: 311-323
Publication/Series: American journal of nuclear medicine and molecular imaging
Volume: 4
Issue: 4
Document type: Journal article
Publisher: E-Century Publishing Corporation

Abstract english

The aim of this investigation was to assess the Ku70/Ku80 complex as a potential target for antibody imaging of prostate cancer. We evaluated the in vivo and ex vivo tumor targeting and biodistribution of the (111)In-labeled human internalizing antibody, INCA-X ((111)In-DTPA-INCA-X antibody), in NMRI-nude mice bearing human PC-3, PC-3M-Lu2 or DU145 xenografts. DTPA-conjugated, non-labeled antibody was pre-administered at different time-points followed by a single intravenous injection of (111)In-DTPA-INCA-X. At 48, 72 and 96 h post-injection, tissues were harvested, and the antibody distribution was determined by measuring radioactivity. Preclinical SPECT/CT imaging of mice with and without the predose was performed at 48 hours post-injection of labeled DTPA-INCA-X. Biodistribution of the labeled antibody showed enriched activity in tumor, spleen and liver. Animals pre-administered with DTPA-INCA-X showed increased tumor uptake and blood content of (111)In-DTPA-INCA-X with reduced splenic and liver uptake. The in vitro and in vivo data presented show that the (111)In-labeled INCA-X antibody is internalized into prostate cancer cells and by pre-administering non-labeled DTPA-INCA-X, we were able to significantly reduce the off target binding and increase the (111)In-DTPA-INCA-X mAb uptake in PC-3, PC-3M-Lu2 and DU145 xenografts. The results are encouraging and identifying the Ku70/Ku80 antigen as a target is worth further investigation for functional imaging of prostate cancer.


  • Radiology, Nuclear Medicine and Medical Imaging


  • Urological cancer, Malmö
  • ISSN: 2160-8407
Sven-Erik Strand
E-mail: sven-erik [dot] strand [at] med [dot] lu [dot] se

Project manager

Systemic Radiation Therapy Group


Professor emeritus

Medical Radiation Physics, Lund